Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies

Clinical Therapeutics

Volumn 23, Issue 8, 2001, Pages 1209-1230

  Bays, Harold E ^a   Moore, Paul B ^b   Drehobl, Margaret A ^c   Rosenblatt, Sidney ^d   Toth, Phillip D ^e   Dujovne, Carlos A ^f   Knopp, Robert H ^g   Lipka, Leslie J ^h   LeBeaut, Alexandre P ^h   Yang, Bo ^h   Mellars, Lillian E ^h   Cuffie Jackson, Cynthia ^h   Veltri, Enrico P ^h  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Center for Clinical Research   (United States)

^c SCRIPPS CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Midwest Institute for Clinical Research   (United States)

^f Kansas Foundation for Clinical Pharmacology   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cholesterol absorption inhibitor; Dose response; Ezetimibe; Hypercholesterolemia; Pooled analysis; SCH 58235

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 17944380533     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80102-8     Document Type: Article

References (51)

1. Epidemiology of coronary heart disease: The Framingham Study
2. Serum cholesterol, lipoproteins, and the risk of coronary heart disease
3. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five-year follow-up of the Seven Countries Study
4. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
7. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
8. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
9. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
10. Lipoprotein metabolism
11. Cholesterol biosynthesis and metabolism
12. Management of hypercholesterolemia
13. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
14. Drugs used in the treatment of hyperdyslipidemias
15. Lipid-altering drugs in development
16. Colesevelam hydrochloride (Cholestagel). A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects
17. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner
18. Regulation of cholesterol metabolism by dietary plant sterols
19. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461
20. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
21. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function
22. The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically
23. The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor
24. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption
25. The hypocholesterolemic activity of the potent cholesterol absorption inhibitor SCH58235 alone and in combination with HMG CoA reductase inhibitors
26. The cholesterol inhibitor ezetimibe inhibits the development of atherosclerosis in apo E knockout (-/-) mice fed low fat and Western diets
27. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese, hyperinsulinemic hamsters
28. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys
29. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor ezetimibe in combination with HMG-CoA reductase inhibitors in dogs
30. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins
31. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo
32. Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin
33. Ezetimibe does not affect the pharmacokinetics of oral contraceptives
34. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide
35. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe
36. Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications
37. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
38. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
39. Comparison of two scoring systems used to monitor diets in outpatient clinical trials
40. Adverse reaction terminology standardization: A report of Schering-Plough's use of the WHO dictionary and the formation of the WHO Adverse Reaction Terminology Users Group (WUG) Consortium
41. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening
42. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study
43. Drug treatment of lipid disorders
44. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity
45. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin
46. Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL-cholesterol
47. Pharmacodynamic interaction between the selective cholesterol absorption inhibitor ezetimibe and lovastatin
48. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin